Siemens Healthineers acquired NEO New Oncology AG from Cologne, Germany which is the initial entry point for Siemens into next generation sequencing-based genomic testing and capabilities for precision medicine and companion diagnostics. The company's cancer genome diagnostic platform NEO will support healthcare professionals to comprehensively obtain molecular information on select targeted cancer therapies.
NEO New Oncology is developing molecular profiling assays for tissue specimens and body liquids, including NEOliquid which is liquid biopsy test for the analysis of genomic profiles of solid tumors from a simple blood sample. NEO New Oncology's high quality 3rd generation hybrid capture technology allows for the analysis of circulating tumor DNA with high accuracy.
We are excited about being part of Siemens Healthineers," says Andreas Jenne, CEO of NEO New Oncology AG. "The global presence will help us to grow and expand into new markets. We want to develop new, integrated solutions for cancer diagnostics with Siemens Healthineers, expand our portfolio of tests and offer services that will help physicians to select the right therapy for their patients."